- Home
- IKT vs EDF Comparison
IKT vs EDF Comparison
Compare IKT & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- EDF
- Stock Information
- Founded
- IKT 2008
- EDF 2010
- Country
- IKT United States
- EDF United States
- Employees
- IKT N/A
- EDF N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- EDF Investment Managers
- Sector
- IKT Health Care
- EDF Finance
- Exchange
- IKT Nasdaq
- EDF Nasdaq
- Market Cap
- IKT 140.5M
- EDF 156.6M
- IPO Year
- IKT 2020
- EDF N/A
- Fundamental
- Price
- IKT $1.85
- EDF $5.02
- Analyst Decision
- IKT Buy
- EDF
- Analyst Count
- IKT 2
- EDF 0
- Target Price
- IKT $8.00
- EDF N/A
- AVG Volume (30 Days)
- IKT 526.2K
- EDF 160.6K
- Earning Date
- IKT 08-13-2025
- EDF 01-01-0001
- Dividend Yield
- IKT N/A
- EDF 13.14%
- EPS Growth
- IKT N/A
- EDF N/A
- EPS
- IKT N/A
- EDF N/A
- Revenue
- IKT N/A
- EDF N/A
- Revenue This Year
- IKT N/A
- EDF N/A
- Revenue Next Year
- IKT N/A
- EDF N/A
- P/E Ratio
- IKT N/A
- EDF N/A
- Revenue Growth
- IKT N/A
- EDF N/A
- 52 Week Low
- IKT $1.12
- EDF $3.51
- 52 Week High
- IKT $4.20
- EDF $5.50
- Technical
- Relative Strength Index (RSI)
- IKT 47.71
- EDF 60.04
- Support Level
- IKT $1.80
- EDF $5.00
- Resistance Level
- IKT $2.09
- EDF $5.11
- Average True Range (ATR)
- IKT 0.14
- EDF 0.05
- MACD
- IKT 0.03
- EDF 0.00
- Stochastic Oscillator
- IKT 54.72
- EDF 72.73
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.